ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 270 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,076,929 | -11.2% | 579,507 | +2.0% | 0.00% | 0.0% |
| Q2 2023 | $13,604,696 | +24.5% | 568,046 | -2.1% | 0.00% | 0.0% |
| Q1 2023 | $10,924,539 | +31.1% | 580,475 | +10.9% | 0.00% | +33.3% |
| Q4 2022 | $8,332,000 | -45.2% | 523,296 | -43.7% | 0.00% | -50.0% |
| Q3 2022 | $15,205,000 | +14.2% | 929,807 | -1.6% | 0.01% | +20.0% |
| Q2 2022 | $13,319,000 | -49.1% | 945,060 | -12.5% | 0.01% | -37.5% |
| Q1 2022 | $26,144,000 | -3.3% | 1,079,541 | -6.8% | 0.01% | +14.3% |
| Q4 2021 | $27,038,000 | +44.2% | 1,158,298 | +2.6% | 0.01% | +16.7% |
| Q3 2021 | $18,750,000 | -40.8% | 1,128,780 | -13.1% | 0.01% | -40.0% |
| Q2 2021 | $31,675,000 | -49.6% | 1,298,738 | -46.6% | 0.01% | -52.4% |
| Q1 2021 | $62,791,000 | -7.2% | 2,434,051 | +92.3% | 0.02% | -12.5% |
| Q4 2020 | $67,652,000 | +34.9% | 1,265,510 | +4.1% | 0.02% | +20.0% |
| Q3 2020 | $50,160,000 | -52.2% | 1,216,007 | -43.9% | 0.02% | -55.6% |
| Q2 2020 | $105,028,000 | +56.2% | 2,166,974 | +36.1% | 0.04% | +28.6% |
| Q1 2020 | $67,260,000 | +79.0% | 1,592,016 | +81.3% | 0.04% | +118.8% |
| Q4 2019 | $37,565,000 | +4.3% | 878,100 | -12.2% | 0.02% | 0.0% |
| Q3 2019 | $36,006,000 | +186.7% | 1,000,494 | +112.9% | 0.02% | +166.7% |
| Q2 2019 | $12,559,000 | -12.2% | 469,872 | -11.8% | 0.01% | -14.3% |
| Q1 2019 | $14,301,000 | +142.7% | 532,669 | +46.1% | 0.01% | +133.3% |
| Q4 2018 | $5,893,000 | -22.1% | 364,491 | -0.1% | 0.00% | 0.0% |
| Q3 2018 | $7,561,000 | -47.4% | 364,960 | -61.3% | 0.00% | -50.0% |
| Q2 2018 | $14,385,000 | -26.5% | 942,228 | +8.1% | 0.01% | -33.3% |
| Q1 2018 | $19,573,000 | -23.2% | 871,320 | +3.0% | 0.01% | -25.0% |
| Q4 2017 | $25,470,000 | -24.2% | 845,940 | -5.2% | 0.01% | -25.0% |
| Q3 2017 | $33,600,000 | +18.4% | 892,006 | -12.3% | 0.02% | +14.3% |
| Q2 2017 | $28,380,000 | -6.4% | 1,017,552 | +15.3% | 0.01% | -12.5% |
| Q1 2017 | $30,329,000 | +179.6% | 882,722 | +134.7% | 0.02% | +166.7% |
| Q4 2016 | $10,847,000 | +10.2% | 376,117 | +21.5% | 0.01% | 0.0% |
| Q3 2016 | $9,846,000 | -29.4% | 309,581 | -28.0% | 0.01% | -25.0% |
| Q2 2016 | $13,953,000 | +12.8% | 429,965 | -2.8% | 0.01% | +14.3% |
| Q1 2016 | $12,368,000 | +45.7% | 442,318 | +85.7% | 0.01% | +40.0% |
| Q4 2015 | $8,489,000 | +135.3% | 238,170 | +118.3% | 0.01% | +150.0% |
| Q3 2015 | $3,607,000 | -0.7% | 109,095 | +25.7% | 0.00% | 0.0% |
| Q2 2015 | $3,634,000 | +23.2% | 86,780 | -4.1% | 0.00% | 0.0% |
| Q1 2015 | $2,950,000 | -70.9% | 90,507 | -71.7% | 0.00% | -66.7% |
| Q4 2014 | $10,144,000 | +7.6% | 319,521 | -16.1% | 0.01% | 0.0% |
| Q3 2014 | $9,428,000 | +4.8% | 380,781 | -4.4% | 0.01% | +20.0% |
| Q2 2014 | $9,000,000 | -33.2% | 398,444 | -28.0% | 0.01% | -37.5% |
| Q1 2014 | $13,463,000 | +114.0% | 553,330 | +119.8% | 0.01% | +100.0% |
| Q4 2013 | $6,291,000 | -14.2% | 251,782 | -5.7% | 0.00% | -20.0% |
| Q3 2013 | $7,336,000 | +39.0% | 267,048 | -8.2% | 0.01% | +25.0% |
| Q2 2013 | $5,278,000 | – | 290,785 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |